CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

In May of that year, a team at the University of California, Berkeley, filed its first patent application in the U.S. for CRISPR-Cas9. In December, a different team at the Broad Institute of MIT ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Barclays on May 9, 2025. The analyst firm set a price target for $42.00 expecting CRSP to rise to within 12 months (a ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

The Chief of Air Staff (CAS), Air Marshal Hassan Abubakar, has charged personnel of the Nigerian Air Force to always exhibit high level of professionalism in the discharge of their duties in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Visit a quote page and your recently viewed tickers will be displayed here.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.